Gut

CD48 is a novel immune checkpoint on tumour‐associated macrophages in hepatocellular carcinoma

Background Hepatocellular carcinoma (HCC) is a leading cause of cancer mortality with limited therapeutic options. Despite ...
Opinion
GutOpinion

Road to IBD prevention in the Global South: a conceptual framework modelling from non-communicable diseases

IBD is rising worldwide and is now a global disease. With the expanding armamentarium of medical therapies, including biologics and small molecules, there is a decline in hospitalisation rates and IBD ...
Gut

Recovery of HBV-specific B cell function after discontinuation of nucleos(t)ide analogue therapy: new insight and future challenges

In hepatitis B virus (HBV) infection, the capacity to mount a functional virus-specific T-cell response has long been considered the principal, if not the sole, immunological determinant of viral ...
Gut

Proton pump inhibitors use and risk of inflammatory bowel disease in children

A recent randomised controlled trial showed that proton pump inhibitors (PPIs), compared with histamine-2 receptor antagonists (H2RAs), induce greater gut microbiome alterations and oral-to-gut ...
Gut

Global guidelines on diverticular disease of the colon: the Fiesole Consensus report

Introduction Colonic diverticulosis is the most common structural abnormality of the colon in developed countries, with an increasing global prevalence. Approximately 20–25% of affected individuals ...
Gut

Role of A2 beta casein in milk-induced eosinophilic oesophagitis: novel in-vivo and in-vitro findings

We read with interest the article by Santacroce about personalised medicine in eosinophilic oesophagitis (EoE) and the ...
gut.bmj

Individualised therapy is more cost-effective than dose intensification in patients with Crohn’s disease who lose response to anti-TNF treatment: a randomised, controlled trial

4 Department of Hepatology and Gastroenterology V, Aarhus Hospital, Aarhus, Denmark 5 Department of Gastroenterology, Hvidovre Hospital, Hvidovre, Denmark 6 Department of Medical Gastroenterology S, ...
gut.bmj

Severe clinical outcomes of COVID-19 associated with proton pump inhibitors: a nationwide cohort study with propensity score matching

Objective The adverse effects of proton pump inhibitors (PPIs) have been documented for pneumonia; however, there is no consensus regarding whether the use of PPIs might be harmful regarding the risk ...
gut.bmj

What to do about the leaky gut

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be ...
gut.bmj

Long-chain sulfatide enrichment is an actionable metabolic vulnerability in intraductal papillary mucinous neoplasm (IPMN)-associated pancreatic cancers

Background We conducted an integrated cross-species spatial assessment of transcriptomic and metabolomic alterations associated with progression of intraductal papillary mucinous neoplasms (IPMNs), ...
gut.bmj

SARS-CoV-2 induced diarrhoea as onset symptom in patient with COVID-19

We read with great interest the recent publication by Kumar et al , concerning gastrointestinal tract (GIT) symptoms (vomiting, diarrhoea and abdominal pain) among hospitalised children admitted with ...
gut.bmj

Glucagon-like peptide-1 receptor agonist use is associated with a lower risk of major adverse liver-related outcomes: a meta-analysis of observational cohort studies

Background Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have shown promising effects on liver histology in phase 2 trials enrolling patients with metabolic dysfunction-associated steatotic ...